RU2001130903A - Фармацевтические композиции, содержащие ирбесартан - Google Patents
Фармацевтические композиции, содержащие ирбесартанInfo
- Publication number
- RU2001130903A RU2001130903A RU2001130903/15A RU2001130903A RU2001130903A RU 2001130903 A RU2001130903 A RU 2001130903A RU 2001130903/15 A RU2001130903/15 A RU 2001130903/15A RU 2001130903 A RU2001130903 A RU 2001130903A RU 2001130903 A RU2001130903 A RU 2001130903A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- irbesartan
- diuretic
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Фармацевтическая композиция, отличающаяся тем, что указанная композиция содержит в % по весу: от 20 до 70% ирбесартана, от 2 до 33% диуретика, причем суммарное количество ирбесартана и диуретика не превышает 85 вес.%, от 1 до 70% наполнителя, от 2 до 20 вес.% связующего, от 1 до 10% дезинтегратора, от 0,1 до 5% антиадгезива и от 0,2 до 1,5% смазывающего агента.
2. Фармацевтическая композиция по п.1, отличающаяся тем, что она дополнительно содержит до 2% красителя.
3. Фармацевтическая композиция по любому из п.1 или 2, отличающаяся тем, что диуретик представляет собой одно или несколько соединений, выбранных из группы, включающей гидрохлортиазид, бендрофлуметиазид (бензилгидрофлуметиазид), бензтиазид, хлортиазид, хлорталидон, циклотиазид, гидрофлуметиазид, метиклотиазид, метолазон, политиазид, хинэтазон и трихлорметиазид.
4. Фармацевтическая композиция по п.1, отличающаяся тем, что она включает, в % по весу: от 20 до 50% ирбесартана, от 2 до 20% диуретика, от 1 до 70% наполнителя, от 10 до 20% связующего, от 4 до 6% дезинтегратора, от 0,5 до 1,0% антиадгезива, от 0,5 до 1,5% смазывающего агента.
5. Фармацевтическая композиция по любому из п.1 или 2, отличающаяся тем, что диуретиком является гидрохлортиазид.
6. Фармацевтическая композиция по п.5, отличающаяся тем, что диуретиком является гидрохлортиазид, наполнителем является лактоза водная и микрокристаллическая целлюлоза, связующим является прежелатинированный крахмал, дезинтегратором является натрий-кроскармелоза, антиадгезивом является диоксид кремния, и смазывающим агентом является стеарат магния.
7. Фармацевтическая композиция по п.6, отличающаяся тем, что она включает, в % по весу: 50% ирбесартана, 8,33% гидрохлортиазида, 4,72% лактозы водной, 15,0% прежелатинированного крахмала, 5,0% натрий-кроскармелозы, 15% микрокристаллической целлюлозы, 0,75% диоксида кремния, 1,0% стеарата магния, 0,1% оксида железа красного и 0,1% оксида железа желтого.
8. Фармацевтическая композиция по п.6, отличающаяся тем, что она включает, в % по весу: 50% ирбесартана, 4,17% гидрохлортиазида, 8,88% лактозы водной, 15,0% прежелатинированного крахмала, 5,0% натрий-кроскармелозы, 15% микрокристаллической целлюлозы, 0,75% диоксида кремния, 1,0% стеарата магния, 0,1% оксида железа красного и 0,1% оксида железа желтого.
9. Фармацевтическая композиция по любому из пп.1-8, отличающаяся тем, что она сформована в виде таблетки.
10. Таблетка, отличающаяся тем, что она сформована из композиции по любому из пп.1-9 и при этом обладает такой растворимостью, что 80% или более ирбесартана или его соли, содержащихся в указанной таблетке, растворяется в течение 30 минут.
11. Таблетка по п.10, отличающаяся тем, что ее общий вес составляет от 50 до 600 мг.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47261895A | 1995-06-07 | 1995-06-07 | |
US472,618 | 1995-06-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96111030/14A Division RU2181590C2 (ru) | 1995-06-07 | 1996-06-06 | Фармацевтические композиции, содержащие ирбесартан |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2210368C1 RU2210368C1 (ru) | 2003-08-20 |
RU2001130903A true RU2001130903A (ru) | 2004-02-27 |
Family
ID=23876256
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2001130903/14A RU2210368C1 (ru) | 1995-06-07 | 1996-06-06 | Фармацевтические композиции, содержащие ирбесартан |
RU96111030/14A RU2181590C2 (ru) | 1995-06-07 | 1996-06-06 | Фармацевтические композиции, содержащие ирбесартан |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96111030/14A RU2181590C2 (ru) | 1995-06-07 | 1996-06-06 | Фармацевтические композиции, содержащие ирбесартан |
Country Status (23)
Country | Link |
---|---|
EP (2) | EP0747050B2 (ru) |
JP (1) | JP3162626B2 (ru) |
KR (1) | KR100442719B1 (ru) |
CN (1) | CN1149083C (ru) |
AR (2) | AR002350A1 (ru) |
AT (2) | ATE248594T1 (ru) |
AU (1) | AU702651B2 (ru) |
CA (1) | CA2177772C (ru) |
CZ (1) | CZ291532B6 (ru) |
DE (2) | DE69638348D1 (ru) |
DK (2) | DK1275391T3 (ru) |
ES (2) | ES2363127T3 (ru) |
HK (1) | HK1002384A1 (ru) |
HU (1) | HU229369B1 (ru) |
IL (1) | IL118309A (ru) |
NO (2) | NO310495B1 (ru) |
NZ (2) | NZ329547A (ru) |
PL (1) | PL184893B1 (ru) |
PT (2) | PT747050E (ru) |
RU (2) | RU2210368C1 (ru) |
SG (1) | SG49956A1 (ru) |
TW (1) | TW442301B (ru) |
ZA (1) | ZA964337B (ru) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2338256C (en) * | 1998-07-20 | 2008-09-23 | Smithkline Beecham Corporation | Bioenhanced formulations comprising eprosartan in oral solid dosage form |
SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
JP4565456B2 (ja) * | 1999-11-02 | 2010-10-20 | 塩野義製薬株式会社 | 着色顆粒の色素定着法 |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US8980870B2 (en) | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
TR200301553A1 (tr) * | 2003-09-18 | 2005-10-21 | Nobel �La� Sanay�� Ve T�Caret A.�. | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar |
JP2005126338A (ja) * | 2003-10-21 | 2005-05-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 心不全治療剤 |
WO2005089720A1 (en) * | 2004-03-10 | 2005-09-29 | Ranbaxy Laboratories Limited | Valsartan tablets and the process for the preparation thereof |
EP1750862B1 (en) * | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
WO2006013545A1 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of irbesartan |
EP1928409B1 (en) | 2005-09-12 | 2012-09-12 | Actelion Pharmaceuticals Ltd. | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
WO2007061829A2 (en) * | 2005-11-17 | 2007-05-31 | Novartis Ag | Pharmaceutical composition |
ES2340701T3 (es) * | 2006-01-09 | 2010-06-08 | Krka, D.D., Novo Mesto | Composicion farmaceutica solida que comprende irbesartan. |
DE102006006588A1 (de) * | 2006-02-13 | 2007-08-16 | Ratiopharm Gmbh | Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung |
NZ573566A (en) | 2006-06-12 | 2012-01-12 | Schering Corp | Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders |
CA2654890C (en) | 2006-06-16 | 2015-10-06 | Lek Pharmaceuticals D.D. | Pharmaceutical composition |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
WO2008125388A1 (en) * | 2007-04-17 | 2008-10-23 | Ratiopharm Gmbh | Pharmaceutical compositions comprising irbesartan |
JP5683058B2 (ja) * | 2007-04-27 | 2015-03-11 | ニプロ株式会社 | 経口固形製剤及びその製造方法 |
TR200703568A1 (tr) | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
PL2065035T3 (pl) | 2007-11-28 | 2011-02-28 | Lesvi Laboratorios Sl | Preparaty farmaceutyczne zawierające irbesartan |
CN101327213B (zh) * | 2008-06-20 | 2010-10-13 | 海南锦瑞制药股份有限公司 | 厄贝沙坦氢氯噻嗪药用组合物及其制备方法 |
JP5296456B2 (ja) * | 2008-08-26 | 2013-09-25 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
US9387249B2 (en) | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
US9173848B2 (en) * | 2009-06-30 | 2015-11-03 | Sanofi | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
WO2011010316A1 (en) * | 2009-07-20 | 2011-01-27 | Hetero Research Foundation | Pharmaceutical compositions of irbesartan |
DK2498756T4 (da) * | 2009-11-09 | 2023-03-20 | Wyeth Llc | Tabletformuleringer af neratinibmaleat |
ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
JP4974255B2 (ja) * | 2010-03-16 | 2012-07-11 | 塩野義製薬株式会社 | アンジオテンシンii受容体拮抗剤の配合剤 |
JP5459670B2 (ja) * | 2010-05-07 | 2014-04-02 | 塩野義製薬株式会社 | 着色顆粒の色素定着化剤 |
US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
EP2929877A1 (en) * | 2010-07-08 | 2015-10-14 | ratiopharm GmbH | Oral dosage form of deferasirox |
JP6081376B2 (ja) * | 2011-12-28 | 2017-02-15 | ニプロ株式会社 | アンギオテンシンii拮抗作用を有する化合物を含有する固形医薬組成物 |
DK2851075T3 (da) | 2012-05-14 | 2022-01-31 | Shionogi & Co | Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat |
ES2821528T3 (es) | 2012-11-14 | 2021-04-26 | Grace W R & Co | Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado |
JP5714652B2 (ja) * | 2013-06-13 | 2015-05-07 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
JP6238921B2 (ja) * | 2014-02-17 | 2017-11-29 | 大原薬品工業株式会社 | イルベサルタンを含有する錠剤 |
JP5978335B2 (ja) * | 2015-03-11 | 2016-08-24 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
JP6199922B2 (ja) * | 2015-03-20 | 2017-09-20 | 大原薬品工業株式会社 | 化学的な安定性が向上したイルベサルタン含有錠剤 |
JP6445923B2 (ja) * | 2015-04-22 | 2018-12-26 | ダイト株式会社 | イルベサルタン含有錠剤の調製方法 |
JP6737060B2 (ja) * | 2015-09-11 | 2020-08-05 | ニプロ株式会社 | イルベサルタンを含有する医薬組成物の製造方法 |
JP6151413B2 (ja) * | 2016-07-25 | 2017-06-21 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
JP2017141299A (ja) * | 2017-05-24 | 2017-08-17 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
JP6233911B2 (ja) * | 2017-08-22 | 2017-11-22 | 大原薬品工業株式会社 | 化学的な安定性が向上したイルベサルタン含有錠剤 |
JP2018009032A (ja) * | 2017-10-19 | 2018-01-18 | 大原薬品工業株式会社 | 化学的な安定性が向上したイルベサルタン含有錠剤 |
CN108434112A (zh) * | 2018-06-08 | 2018-08-24 | 华益药业科技(安徽)有限公司 | 一种厄贝沙坦片及其制备方法 |
JP2018168185A (ja) * | 2018-07-05 | 2018-11-01 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
PH12018000390A1 (en) * | 2018-11-20 | 2020-09-28 | Novex Science Pte Ltd | Carbocysteine and zinc tablet |
JP2019203031A (ja) * | 2019-09-06 | 2019-11-28 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3744317C1 (de) | 1987-12-28 | 1989-05-24 | Rudolf Dr Rer Nat Kuerner | Verwendung von Calciumsulfat zur Verbesserung der Fermentierung organischer Abfallstoffe |
EP0400835A1 (en) | 1989-05-15 | 1990-12-05 | Merck & Co. Inc. | Substituted benzimidazoles as angiotensin II antagonists |
US5164407A (en) | 1989-07-03 | 1992-11-17 | Merck & Co., Inc. | Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists |
NZ237476A (en) * | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
IL99372A0 (en) * | 1990-09-10 | 1992-08-18 | Ciba Geigy Ag | Azacyclic compounds |
IS1756B (is) | 1991-02-21 | 2000-12-28 | Sankyo Company Limited | Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða |
EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
WO1994009778A1 (en) * | 1992-10-26 | 1994-05-11 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
EP0629408A1 (en) * | 1993-06-16 | 1994-12-21 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Combination of angiotensin converting enzyme inhibitors and AII antagonists |
US5541209A (en) * | 1994-08-22 | 1996-07-30 | Bristol-Myers Squibb Company | Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative |
FR2725987B1 (fr) * | 1994-10-19 | 1997-01-10 | Sanofi Sa | Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive |
-
1996
- 1996-05-16 TW TW085105820A patent/TW442301B/zh not_active IP Right Cessation
- 1996-05-17 NZ NZ329547A patent/NZ329547A/en not_active IP Right Cessation
- 1996-05-17 NZ NZ286612A patent/NZ286612A/en not_active IP Right Cessation
- 1996-05-17 IL IL11830996A patent/IL118309A/xx not_active IP Right Cessation
- 1996-05-27 SG SG1996009899A patent/SG49956A1/en unknown
- 1996-05-28 ZA ZA9604337A patent/ZA964337B/xx unknown
- 1996-05-30 CA CA002177772A patent/CA2177772C/en not_active Expired - Fee Related
- 1996-06-05 CZ CZ19961634A patent/CZ291532B6/cs not_active IP Right Cessation
- 1996-06-05 KR KR1019960019949A patent/KR100442719B1/ko not_active IP Right Cessation
- 1996-06-06 AU AU54763/96A patent/AU702651B2/en not_active Ceased
- 1996-06-06 HU HU9601564A patent/HU229369B1/hu not_active IP Right Cessation
- 1996-06-06 AR AR10297996A patent/AR002350A1/es not_active Application Discontinuation
- 1996-06-06 NO NO19962387A patent/NO310495B1/no not_active IP Right Cessation
- 1996-06-06 RU RU2001130903/14A patent/RU2210368C1/ru active
- 1996-06-06 RU RU96111030/14A patent/RU2181590C2/ru active
- 1996-06-07 AT AT96304291T patent/ATE248594T1/de active
- 1996-06-07 JP JP14557996A patent/JP3162626B2/ja not_active Expired - Lifetime
- 1996-06-07 PT PT96304291T patent/PT747050E/pt unknown
- 1996-06-07 ES ES02016237T patent/ES2363127T3/es not_active Expired - Lifetime
- 1996-06-07 DK DK02016237.6T patent/DK1275391T3/da active
- 1996-06-07 DK DK96304291.6T patent/DK0747050T4/da active
- 1996-06-07 PT PT02016237T patent/PT1275391E/pt unknown
- 1996-06-07 DE DE69638348T patent/DE69638348D1/de not_active Expired - Lifetime
- 1996-06-07 AT AT02016237T patent/ATE503478T1/de active
- 1996-06-07 CN CNB961068329A patent/CN1149083C/zh not_active Expired - Lifetime
- 1996-06-07 ES ES96304291T patent/ES2205000T5/es not_active Expired - Lifetime
- 1996-06-07 EP EP96304291A patent/EP0747050B2/en not_active Expired - Lifetime
- 1996-06-07 PL PL96314670A patent/PL184893B1/pl unknown
- 1996-06-07 DE DE69629755T patent/DE69629755T3/de not_active Expired - Lifetime
- 1996-06-07 EP EP02016237A patent/EP1275391B1/en not_active Expired - Lifetime
-
1998
- 1998-01-27 HK HK98100693A patent/HK1002384A1/xx not_active IP Right Cessation
-
2000
- 2000-09-22 NO NO20004743A patent/NO310393B1/no not_active IP Right Cessation
-
2006
- 2006-06-16 AR ARP060102579A patent/AR054782A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2001130903A (ru) | Фармацевтические композиции, содержащие ирбесартан | |
RU96111030A (ru) | Фармацевтические композиции, содержащие ирбесартан | |
CA2568640C (en) | Pharmaceutical composition containing irbesartan | |
EP1310245B1 (en) | Clopidogrel bisulfate tablet formulation | |
US4255413A (en) | Gelatin capsule dosage unit containing triamterene | |
US5006344A (en) | Fosinopril tablet formulations | |
NO980669L (no) | Orale raskt-opplöselige blandinger for dopaminagonister | |
US4327080A (en) | Novel Bendroflumethiazide formulations and method | |
KR920019340A (ko) | 최적화된 정제 제제 | |
AR036658A1 (es) | Formulacion de dosificacion oral de fundicion instantanea | |
CA2378428A1 (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
US3865935A (en) | Tableting of erythromycin base | |
KR860002270A (ko) | 니트렌디핀을 함유하는 고상 약제 및 그의 제조방법 | |
PT94512A (pt) | Processo para a preparacao de composicoes herbicidas aperfeicoadas contendo um derivado de bipiridilio com propriedades herbicidas | |
CA2044484A1 (en) | Hexahydroazepine derivatives, a process for their preparation and pharmaceutical compositions containing them | |
US3348999A (en) | Compositions to enhance the learning rate and retention level in animals comprising 2-imino-5-phenyl-4-oxazolidinone and a relatively insoluble base | |
AU629288B2 (en) | Low dose benazepril and thiazide diuretic composition | |
CA1148860A (en) | Gelatin capsule dosage unit containing triamterene | |
JPH0141607B2 (ru) | ||
GB1293329A (en) | Pharmaceutical compositions | |
CA2420056A1 (en) | 1-amino-alkylcyclohexanes as trypanocidal agents | |
Nathwani et al. | New Triazole Antifungal Agents (Fluconazole and Itraconazole) in the Treatment of HIV–related Gastrointestinal Candidiasis | |
JP2935220B6 (ja) | 安定性良好な医薬組成物 | |
TH30909A (th) | เม็ดเล็กสำหรับการเตรียมองค์ประกอบแตกตัวเร็วและละลายเร็วที่มีปริมาณยาสูง | |
TH57759B (th) | ยาเม็ดที่มีการปลดปล่อยในทันที |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD4A | Correction of name of patent owner |